Personal tools

MCL coexpression mm9:259: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
No edit summary
No edit summary
Line 6: Line 6:
|ontology_enrichment_disease=
|ontology_enrichment_disease=
|ontology_enrichment_uberon=UBERON:0005172!1.41e-26!49;UBERON:0005173!1.41e-26!49;UBERON:0002417!1.41e-26!49;UBERON:0000916!1.41e-26!49;UBERON:0009569!1.63e-26!66;UBERON:0005177!1.66e-21!79;UBERON:0002107!5.08e-20!22;UBERON:0007499!5.08e-20!22;UBERON:0006925!5.08e-20!22;UBERON:0009497!5.08e-20!22;UBERON:0000015!5.08e-20!22;UBERON:0002423!5.08e-20!22;UBERON:0006235!5.08e-20!22;UBERON:0008835!5.08e-20!22;UBERON:0003894!5.08e-20!22;UBERON:0004161!5.08e-20!22;UBERON:0008836!5.08e-20!22;UBERON:0009854!9.55e-19!23;UBERON:0009856!9.55e-19!23;UBERON:0002100!1.49e-16!90;UBERON:0002365!1.62e-16!25;UBERON:0002330!1.62e-16!25;UBERON:0003104!1.23e-12!61;UBERON:0009142!1.23e-12!61;UBERON:0005256!1.74e-12!45;UBERON:0000466!8.84e-11!79;UBERON:0001041!1.75e-09!80;UBERON:0002368!1.11e-07!60;UBERON:0003914!7.93e-07!47
|ontology_enrichment_uberon=UBERON:0005172!1.41e-26!49;UBERON:0005173!1.41e-26!49;UBERON:0002417!1.41e-26!49;UBERON:0000916!1.41e-26!49;UBERON:0009569!1.63e-26!66;UBERON:0005177!1.66e-21!79;UBERON:0002107!5.08e-20!22;UBERON:0007499!5.08e-20!22;UBERON:0006925!5.08e-20!22;UBERON:0009497!5.08e-20!22;UBERON:0000015!5.08e-20!22;UBERON:0002423!5.08e-20!22;UBERON:0006235!5.08e-20!22;UBERON:0008835!5.08e-20!22;UBERON:0003894!5.08e-20!22;UBERON:0004161!5.08e-20!22;UBERON:0008836!5.08e-20!22;UBERON:0009854!9.55e-19!23;UBERON:0009856!9.55e-19!23;UBERON:0002100!1.49e-16!90;UBERON:0002365!1.62e-16!25;UBERON:0002330!1.62e-16!25;UBERON:0003104!1.23e-12!61;UBERON:0009142!1.23e-12!61;UBERON:0005256!1.74e-12!45;UBERON:0000466!8.84e-11!79;UBERON:0001041!1.75e-09!80;UBERON:0002368!1.11e-07!60;UBERON:0003914!7.93e-07!47
|tfbs_overrepresentation_for_novel_motifs=0.2121,0.186944,0.0488323,0.554666,0.982854,0.279466,0.401081,0.339247,0.842622,0.0451956,0.340369,0.384124,0.188374,0.418601,0.23585,0,0.259755,0.383396,0.0717318,0.438025,0.339522,0.0896544,0.133942,0.975203,0.4261,0.458764,0.446281,0.306197,0.526046,0.291087,1.01207,0.892346,0.193804,0.115937,0.0953314,0.105131,0.35459,0.11908,0.51446,0.418456,0.203128,0.0874315,0.0344378,1.07664,0.087885,0.248078,0.204367,0.326867,0.644951,0.534336,0.691061,0.964411,0.268737,1.14457,1.17633,0.428923,1.72298,0.114218,0.411486,0.42597,0.320373,0.172475,0.632222,0.239273,0.144946,0.268299,0.584509,0.907487,0.316778,0.768874,0.666619,1.12567,0.0215355,0.494514,0.0157647,0.529441,0.564968,0.196848,1.49968,0.347468,0.201574,0.272401,0.171576,3.54795,0.397678,0.00151573,0.0183543,0.897143,1.12833,1.06309,0.64713,1.03749,0.34595,0.685263,0.0529479,0.254122,1.06751,0.348163,0.204536,0.224173,0.0689321,0.335693,0.436484,0.247661,0.246912,0.0872264,0.290513,1.09904,0.15524,0.148131,2.21318,0.437975,0.349606,0.70635,0.653522,0.388768,0.00410246,0.95383,0.260696,0.345519,0.499163,0.224692,0.151457,0.196253,0.702969,0.310043,0.412705,0.340627,1.42573,0.223308,0.422342,0.0723704,0.556974,3.49239,0.673182,0.0865898,0.061587,0.296517,0.628575,1.42304,1.03234,0.588705,0.4794,0.910596,0.242322,0.295293,0.206447,1.38398,0.486947,0.0836696,0.0351966,0.00084391,0.452434,0.0465279,0.145874,0.522448,0.500553,0.479846,0.209338,0.0614775,0.637161,0.396979,0.310383,0.201723,0.239991,1.99949,0.178463,0.381906,0.00606109
}}
}}

Revision as of 18:04, 26 November 2012


Phase1 CAGE Peaks

 Short description
Mm9::chr10:127188729..127188740,-p3@Gpr182
Mm9::chr10:127188763..127188793,-p1@Gpr182
Mm9::chr10:127188795..127188807,-p2@Gpr182
Mm9::chr10:58904456..58904461,-p6@Oit3
Mm9::chr10:58904496..58904530,-p1@Oit3
Mm9::chr10:58904532..58904548,-p3@Oit3
Mm9::chr10:86470760..86470776,-p1@Stab2
Mm9::chr11:101108238..101108249,+p7@Ramp2
Mm9::chr11:101108274..101108295,+p4@Ramp2
Mm9::chr14:73637960..73637972,+p3@Lpar6
Mm9::chr14:8800226..8800241,-p@chr14:8800226..8800241
-
Mm9::chr14:8826519..8826534,-p1@Dnase1l3
Mm9::chr14:8826705..8826731,-p2@Dnase1l3
Mm9::chr14:8826736..8826741,-p7@Dnase1l3
Mm9::chr17:26145823..26145867,-p@chr17:26145823..26145867
-
Mm9::chr17:74154223..74154241,+p1@Ehd3
Mm9::chr19:57349285..57349290,-p@chr19:57349285..57349290
-
Mm9::chr1:172906175..172906237,-p1@Fcgr2b
Mm9::chr1:172906243..172906251,-p4@Fcgr2b
Mm9::chr1:45984844..45984854,-p@chr1:45984844..45984854
-
Mm9::chr2:14151017..14151031,+p1@Mrc1
Mm9::chr3:129236571..129236575,+p@chr3:129236571..129236575
+
Mm9::chr4:129255756..129255761,-p3@Fam167b
Mm9::chr4:86490683..86490694,+p12@Dennd4c
Mm9::chr6:129347496..129347516,+p1@Clec1b
Mm9::chr6:23048067..23048077,-p@chr6:23048067..23048077
-
Mm9::chr6:23048089..23048097,-p@chr6:23048089..23048097
-
Mm9::chr6:23048103..23048116,-p@chr6:23048103..23048116
-
Mm9::chr7:105233983..105234029,-p@chr7:105233983..105234029
-
Mm9::chr8:3720640..3720682,-p1@Clec4g
Mm9::chr8:40721510..40721528,+p@chr8:40721510..40721528
+
Mm9::chr8:40721546..40721559,+p@chr8:40721546..40721559
+


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data


GO IDGO nameFDR corrected p-value
GO:0030246carbohydrate binding0.00191584833239487
GO:0010324membrane invagination0.00657334377428434
GO:0006897endocytosis0.00657334377428434
GO:0005529sugar binding0.00666741606348981
GO:0016044membrane organization and biogenesis0.010377638772252
GO:0002713negative regulation of B cell mediated immunity0.0141299554327411
GO:0001811negative regulation of type I hypersensitivity0.0141299554327411
GO:0002890negative regulation of immunoglobulin mediated immune response0.0141299554327411
GO:0005509calcium ion binding0.0141299554327411
GO:0002704negative regulation of leukocyte mediated immunity0.0158313286891551
GO:0002865negative regulation of acute inflammatory response to antigenic stimulus0.0158313286891551
GO:0002862negative regulation of inflammatory response to antigenic stimulus0.0158313286891551
GO:0002884negative regulation of hypersensitivity0.0158313286891551
GO:0002674negative regulation of acute inflammatory response0.0158313286891551
GO:0002707negative regulation of lymphocyte mediated immunity0.0158313286891551
GO:0016192vesicle-mediated transport0.0158313286891551
GO:0004872receptor activity0.0195047244678391
GO:0002698negative regulation of immune effector process0.0205344390387834
GO:0004871signal transducer activity0.0234621448798781
GO:0060089molecular transducer activity0.0234621448798781
GO:0015027coreceptor, soluble ligand activity0.0234621448798781
GO:0002820negative regulation of adaptive immune response0.0256553949754007
GO:0019864IgG binding0.0256553949754007
GO:0002823negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains0.0256553949754007
GO:0050777negative regulation of immune response0.0284112784656538
GO:0002683negative regulation of immune system process0.0284112784656538
GO:0006309DNA fragmentation during apoptosis0.0298314799756331
GO:0015026coreceptor activity0.0298314799756331
GO:0009986cell surface0.0298314799756331
GO:0001810regulation of type I hypersensitivity0.0298314799756331
GO:0006921cell structure disassembly during apoptosis0.0298314799756331
GO:0030889negative regulation of B cell proliferation0.0298314799756331
GO:0016068type I hypersensitivity0.0298314799756331
GO:0016043cellular component organization and biogenesis0.0307561314100322
GO:0030262apoptotic nuclear changes0.0307561314100322
GO:0019865immunoglobulin binding0.0307561314100322
GO:0050869negative regulation of B cell activation0.0313872998376249
GO:0031348negative regulation of defense response0.0313872998376249
GO:0050728negative regulation of inflammatory response0.0313872998376249
GO:0002889regulation of immunoglobulin mediated immune response0.0313872998376249
GO:0002883regulation of hypersensitivity0.0313872998376249
GO:0002673regulation of acute inflammatory response0.0313872998376249
GO:0002712regulation of B cell mediated immunity0.0313872998376249
GO:0002438acute inflammatory response to antigenic stimulus0.0313872998376249
GO:0002864regulation of acute inflammatory response to antigenic stimulus0.0313872998376249
GO:0002524hypersensitivity0.0313872998376249
GO:0005537mannose binding0.0313872998376249
GO:0006308DNA catabolic process0.0326069972186087
GO:0030139endocytic vesicle0.0326069972186087
GO:0002861regulation of inflammatory response to antigenic stimulus0.0330811956029298
GO:0002437inflammatory response to antigenic stimulus0.0330811956029298
GO:0006911phagocytosis, engulfment0.0330811956029298
GO:0002495antigen processing and presentation of peptide antigen via MHC class II0.0344736754666101
GO:0050766positive regulation of phagocytosis0.0344736754666101
GO:0050764regulation of phagocytosis0.0344736754666101
GO:0005540hyaluronic acid binding0.0344736754666101
GO:0019886antigen processing and presentation of exogenous peptide antigen via MHC class II0.0344736754666101
GO:0002703regulation of leukocyte mediated immunity0.0353289800284238
GO:0002706regulation of lymphocyte mediated immunity0.0353289800284238
GO:0002478antigen processing and presentation of exogenous peptide antigen0.0353289800284238
GO:0008277regulation of G-protein coupled receptor protein signaling pathway0.0353289800284238
GO:0004536deoxyribonuclease activity0.0353289800284238
GO:0002504antigen processing and presentation of peptide or polysaccharide antigen via MHC class II0.0353289800284238
GO:0002697regulation of immune effector process0.0353289800284238
GO:0050672negative regulation of lymphocyte proliferation0.0353289800284238
GO:0032945negative regulation of mononuclear cell proliferation0.0353289800284238
GO:0045807positive regulation of endocytosis0.0373316893855504
GO:0048029monosaccharide binding0.0373316893855504
GO:0030888regulation of B cell proliferation0.0373316893855504
GO:0022411cellular component disassembly0.0374705988820493
GO:0002819regulation of adaptive immune response0.0374705988820493
GO:0002822regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains.0.0374705988820493
GO:0019884antigen processing and presentation of exogenous antigen0.0386276636442263
GO:0016021integral to membrane0.038785723061121
GO:0031224intrinsic to membrane0.0388722406608826
GO:0051250negative regulation of lymphocyte activation0.0403093622187683
GO:0006997nuclear organization and biogenesis0.0413671082796243
GO:0042100B cell proliferation0.0423969618808694
GO:0031347regulation of defense response0.0438293105113802
GO:0051241negative regulation of multicellular organismal process0.0438293105113802
GO:0050727regulation of inflammatory response0.0438293105113802
GO:0051050positive regulation of transport0.0492180015186909
GO:0048002antigen processing and presentation of peptide antigen0.0494899013562665
GO:0030100regulation of endocytosis0.0494899013562665



Relative expression of the co-expression cluster over median <br>Analyst:





Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br><br>uberon_data<br><br>


Uber Anatomy
Ontology termp-valuen
abdomen element1.41e-2649
abdominal segment element1.41e-2649
abdominal segment of trunk1.41e-2649
abdomen1.41e-2649
subdivision of trunk1.63e-2666
trunk region element1.66e-2179
liver5.08e-2022
epithelial sac5.08e-2022
digestive gland5.08e-2022
epithelium of foregut-midgut junction5.08e-2022
anatomical boundary5.08e-2022
hepatobiliary system5.08e-2022
foregut-midgut junction5.08e-2022
hepatic diverticulum5.08e-2022
liver primordium5.08e-2022
septum transversum5.08e-2022
liver bud5.08e-2022
digestive tract diverticulum9.55e-1923
sac9.55e-1923
trunk1.49e-1690
exocrine gland1.62e-1625
exocrine system1.62e-1625
mesenchyme1.23e-1261
entire embryonic mesenchyme1.23e-1261
trunk mesenchyme1.74e-1245
immaterial anatomical entity8.84e-1179
foregut1.75e-0980
endocrine gland1.11e-0760
epithelial tube7.93e-0747


TFBS overrepresentation<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data


Novel motifs




JASPAR motifs


Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}